Genmab A/S
Denmark
429 articles with Genmab A/S
-
Genmab Publishes 2022 Annual Report
2/22/2023
Genmab A/S announced the publication of its Annual Report for 2022.
-
Genmab Announces Initiation of Share Buy-Back Program - February 22, 2023
2/22/2023
Genmab A/S announced that it is initiating a share buy-back program to honor our commitments under our Restricted Stock Unit program.
-
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2022
1/24/2023
Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by Johnson & Johnson were USD 7,977 million in 2022.
-
Genmab Announces Submission of Japan New Drug Application (JNDA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
12/21/2022
Genmab A/S (Nasdaq: GMAB) today announced that the company has submitted a Japan new drug application (JNDA) to the Ministry of Health, Labor and Welfare (MHLW) of Japan for subcutaneous epcoritamab (DuoBody®-CD3xCD20), an investigational bispecific antibody, for the treatment of patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after two or more lines of systemic therapy.
-
Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting
12/11/2022
Genmab A/S announced the results from multiple clinical trials evaluating epcoritamab, an investigational subcutaneous bispecific antibody.
-
Genmab Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (BLA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
11/21/2022
Genmab A/S today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for subcutaneous epcoritamab (DuoBody®-CD3xCD20).
-
Genmab Announces Multiple Abstracts to be Presented at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH)
11/3/2022
Genmab A/S (Nasdaq: GMAB) announced today that 19 abstracts evaluating various investigational medicines in its pipeline have been accepted for presentation at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH), being held at the Ernest N. Morial Convention Center in New Orleans, Louisiana, and virtually, December 10-13.
-
Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma (DLBCL)
10/28/2022
Genmab has Submitted Biologics License Application (BLA) to U.S. Food and Drug Administration (FDA) for epcoritamab.
-
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2022
10/18/2022
Genmab A/S announced that worldwide net trade sales of DARZALEX®,including sales of the subcutaneous product,as reported by Johnson & Johnson were USD 2,052 million in the third quarter of 2022.
-
Major Shareholder Announcement - October 05, 2022
10/5/2022
Genmab A/S announces under reference to Section 30 of the Danish Capital Markets Act that Wellington Management Group LLP has informed us that, as of October 4, 2022, Wellington Management Group LLPthrough shares and financial instruments holds the voting rights to 3,309,527 shares in Genmab A/S, which amounts to 5.03% of the share capital and voting rights in Genmab A/S.
-
Genmab Announces Financial Results for the First Half of 2022
8/10/2022
Genmab Announces Financial Results for the First Half of 2022.
-
Genmab Improves Its 2022 Financial Guidance
8/8/2022
Genmab A/S announced that it is improving its 2022 financial guidance published on May 11, 2022.
-
Genmab and BioNTech Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates
8/5/2022
Genmab A/S (Nasdaq: GMAB) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced an expansion of their global strategic collaboration to develop and commercialize novel immunotherapies for the treatment of cancer patients.
-
BioNTech and Genmab Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates
8/5/2022
BioNTech SE and Genmab A/S announced an expansion of their global strategic collaboration to develop and commercialize novel immunotherapies for the treatment of cancer patients.
-
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2022
7/19/2022
COPENHAGEN, Denmark; July 19, 2022 – Genmab A/S announced that worldwide net trade sales of DARZALEX®,including sales of the subcutaneous formulation,as reported by Johnson & Johnson were USD 1,986 million in the second quarter of 2022.
-
Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
7/18/2022
Genmab A/S announced that AbbVie will submit a conditional marketing authorization application with the European Medicines Agency for subcutaneous epcoritamab, an investigational bispecific antibody, for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma, in the second half of 2022.
-
Genmab to Submit Biologics License Application to U.S. Food and Drug Administration for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
6/30/2022
Genmab A/S (Nasdaq: GMAB) today announced its intent to submit a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) for subcutaneous epcoritamab (DuoBody®-CD3xCD20), an investigational bispecific antibody, for the treatment of patients with relapsed/refractory large B-cell lymphoma (LBCL), in the second half of 2022.
-
Genmab A/S: Major Shareholder Announcement
6/20/2022
Genmab A/S announces under reference to Section 30 of the Danish Capital Markets Act that Wellington Management Group LLP has informed us that, as of June 15, 2022 Wellington Management Group LLP had decreased their holding of shares in Genmab A/S to4.99% of the share capital and voting rights in Genmab A/S, so that through shares and financial instruments they held the voting rights to 3,293,871 shares in Genmab A/S, which amounts to 5.00% of the share capital and voting rights in Genmab A/S.
-
Genmab and AbbVie announce positive data in large b-cell lymphoma, Intra-Cellular's bipolar depression candidate hits the endpoint in Phase III and more.
-
Genmab's Phase II expansion cohort of the EPCORE NHL-1 clinical trial revealed that its investigational bispecific antibody epcoritamab induced a durable response in patients with LBCL.